Fig. 1From: Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter studyProgression-free survival in patients with non-small cell lung cancer responding to pembrolizumab monotherapy. All patients (a), patients stratified by age (b), ECOG PS (c), and number of metastatic organs (d), presence of bone metastasis (e). HR, hazard ratio; CI, confidence interval; PS, performance status; ECOG PS, Eastern Cooperative Oncology Group performance status. Generated using JMP software (version 14; SAS Institute, Cary, NC, USA)Back to article page